Peer-reviewed veterinary case report
Leishmune vaccine stops parasite spread in dogs with visceral
By Nogueira, F S et al.·Published in Vaccine·2005·Faculdade de Medicina Veteriná, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
- Species:
- dog
Plain-English summary
A group of dogs in Brazil were vaccinated with the Leishmune vaccine to protect against canine visceral leishmaniasis, a serious disease caused by parasites. After 11 months, the vaccinated dogs showed no signs of illness and had no detectable parasites in their blood, skin, or lymph nodes, while unvaccinated dogs had significant symptoms and evidence of infection. This suggests that the Leishmune vaccine not only protects vaccinated dogs but also prevents them from spreading the disease to others. The vaccinated dogs remained healthy and non-infectious, making this vaccine an important tool in controlling leishmaniasis.
People also search for: dog leishmaniasis vaccine · symptoms of leishmaniasis in dogs · how to prevent leishmaniasis in dogs
Abstract
Leishmune vaccine is the first licensed vaccine against canine visceral leishmaniasis. It contains the Fucose-Mannose-ligand (FML) antigen of Leishmania donovani. The potential Leishmune vaccine effect on the interruption of the transmission of the disease, was assayed by monitoring, in untreated (n=40) and vaccinated dogs (n=32) of a Brazilian epidemic area: the kala-azar clinical signs, the FML-seropositivity and the Leishmania parasite evidence by immunohistochemistry of skin and PCR for Leishmanial DNA of lymph node and blood samples. On month 11 after vaccination, untreated controls showed: 25% of symptomatic cases, 50% of FML-seropositivity, 56.7% of lymph node PCR, 15.7% of blood PCR and 25% of immunohistochemical positive reactions. The Leishmune-vaccinated dogs showed 100% of seropositivity to FML and a complete absence of clinical signs and of parasites (0%) in skin, lymph node and blood PCR samples (p<0.01). The positivity in FML-ELISA in untreated dogs significantly correlates with the PCR in lymph node samples (p<0.001) and with the increase in number of symptoms (p=0.006) being strong markers of infectiousness. The absence of symptoms and of evidence of Leishmania DNA and parasites in Leishmune-vaccinated animals indicates the non-infectious condition of the Leishmune-vaccinated dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16011864/